EUVIMEDEUVIMED entdecken
Open Access

T cell–nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy

Xin Yang iD, Ye Su iD, Xiaoyun Ye iD, Changjiang Liu iD, Xin Zhao iD, Yuyan Su iD, Qingyu Dong iD, Wenxuan Zeng iD, Xinghua Sui iD, Xiuman Zhou iD, Guanyu Chen iD, Yujia Zhang iD und 2 weitere

Science Advances · 07.08.2026 · 12 (32)

DOI: 10.1126/sciadv.adp2955 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 07.08.2026. Verfasst von Xin Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Swiss National Science Foundation, National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive T cell therapy requires T cells to infiltrate vascular tissues and preserve immune function. In solid tumor treatment, however, the surrounding microenvironment produces abnormal vasculature that impedes T cell infiltration. An approach that enables vascular normalization and enhances adoptive T cell function in parallel is essential for effective therapy but has not been reported. Here, we report the use of lenvatinib (LEN) to induce transient vascular normalization, thereby facilitating T cell infiltration. Moreover, LEN enhances T cell persistence by promoting the differentiation of T cells toward a memory phenotype. Our results indicate that the differentiation is by suppressing the PI3K–AKT–mTOR pathway, which drives effector differentiation, and by activating FOXO1, a transcription factor that promotes memory formation. To coordinate the transient vascular normalization and T cell enhancement, we link LEN-loaded, PD-L1–blocking micelles to T cells through acid-labile click chemistry, forming pH-responsive T cell–nanodrug conjugates. The conjugates synchronize the intratumoral release of LEN and the PD-L1 antagonist peptide OPBP-1, thereby coordinating vascular normalization, T cell differentiation, and checkpoint blockade. In vivo, the conjugates increased intratumoral CD8 + T cells and splenic memory T cells by over sixfold in B16-OVA tumors and achieved complete regression in a subset of MC38-OVA tumors without systemic toxicity, providing a promising strategy for solid tumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-LymphocytesNeoplasmsPhenylurea CompoundsAnimalsMiceHumansTOR Serine-Threonine KinasesCell DifferentiationTumor MicroenvironmentImmunotherapy, AdoptiveProto-Oncogene Proteins c-aktCell Line, Tumor

Substanzen

TOR Serine-Threonine KinasesPhenylurea CompoundsProto-Oncogene Proteins c-akt

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
  • School of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
  • Laboratory for Bio-Iontronics (BION), Institute of Electrical and Micro Engineering, School of Engineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne 1015, Switzerland.

ORCID-Profile: Xin Yang, Ye Su, Xiaoyun Ye, Changjiang Liu, Xin Zhao, Yuyan Su, Qingyu Dong, Wenxuan Zeng, Xinghua Sui, Xiuman Zhou, Guanyu Chen, Yujia Zhang, Dalin Wu, Juan Liu

Förderung

  • Swiss National Science Foundation
  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Shenzhen Science and Technology Program
  • Novartis Foundation for Medical-Biological Research
  • Guangdong Basic and Applied Basic Research Foundation

Zitieren

APA

Yang, X., Su, Y., Ye, X., Liu, C., Zhao, X., Su, Y., Dong, Q., Zeng, W., Sui, X., Zhou, X., Chen, G., Zhang, Y., Wu, D., & Liu, J. (2026). T cell–nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy. Science Advances, 12(32). https://doi.org/10.1126/sciadv.adp2955

Vancouver

Yang X, Su Y, Ye X, Liu C, Zhao X, Su Y, et al. T cell–nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy. Science Advances. 2026;12(32). doi:10.1126/sciadv.adp2955

BibTeX
@article{Yang2026,
  author = {Yang, Xin and Su, Ye and Ye, Xiaoyun and Liu, Changjiang and Zhao, Xin and Su, Yuyan and Dong, Qingyu and Zeng, Wenxuan and Sui, Xinghua and Zhou, Xiuman and Chen, Guanyu and Zhang, Yujia and Wu, Dalin and Liu, Juan},
  title = {T cell–nanodrug conjugates synchronize vascular normalization and immune activation for solid tumor therapy},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {32},
  doi = {10.1126/sciadv.adp2955}
}
Kostenlos starten →